Oruka Therapeutics (ORKA) Other Non-Current Liabilities (2023 - 2025)

Oruka Therapeutics' (ORKA) quarterly Other Non-Current Liabilities came in at $9.7 million in Q3 2025, up 26.08% year-on-year from $7.7 million in Q3 2024, and up 213.5% quarter-over-quarter from $3.1 million in Q2 2025.

Oruka Therapeutics (ORKA) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends

Oruka Therapeutics' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $9.7 million for Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Oruka Therapeutics 949.58 Mn 118.43 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 9.68 Mn
Jun 30, 2025 3.09 Mn
Mar 31, 2025 1.42 Mn
Sep 30, 2024 7.68 Mn
Sep 30, 2023 432,000.00
Jun 30, 2023 432,000.00